{"id":"https://openalex.org/W2012252789","doi":"https://doi.org/10.1097/ftd.0b013e3181fa57fe","title":"Effect of Cyamemazine on the Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: A Preliminary Retrospective Study","display_name":"Effect of Cyamemazine on the Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: A Preliminary Retrospective Study","publication_year":2010,"publication_date":"2010-11-10","ids":{"openalex":"https://openalex.org/W2012252789","doi":"https://doi.org/10.1097/ftd.0b013e3181fa57fe","mag":"2012252789","pmid":"https://pubmed.ncbi.nlm.nih.gov/21068648"},"language":"en","primary_location":{"id":"doi:10.1097/ftd.0b013e3181fa57fe","doi":"https://doi.org/10.1097/ftd.0b013e3181fa57fe","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ftd.0b013e3181fa57fe","pdf_url":null,"source":{"id":"https://openalex.org/S179268941","display_name":"Therapeutic Drug Monitoring","issn_l":"0163-4356","issn":["0163-4356","1536-3694"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Drug Monitoring","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111728405","display_name":"F. Lancelin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124863","display_name":"Centre Hospitalier Sainte-Anne","ror":"https://ror.org/02kxjxy06","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124863"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Fr\u00e9d\u00e9rique Lancelin","raw_affiliation_strings":["Department of Laboratory Medicine, Section of Psychopharmacology, Centre Hospitalier Sainte-Anne, Paris, France. f.lancelin@ch-sainte-anne.fr"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Laboratory Medicine, Section of Psychopharmacology, Centre Hospitalier Sainte-Anne, Paris, France. f.lancelin@ch-sainte-anne.fr","institution_ids":["https://openalex.org/I4210124863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051224873","display_name":"Elsa Bourcier","orcid":"https://orcid.org/0000-0003-4605-4963","observed_orcids":["https://orcid.org/0000-0003-4605-4963"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elsa Bourcier","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042348281","display_name":"Val\u00e9rie Dauriac\u2010Le Masson","orcid":"https://orcid.org/0000-0003-0512-5876","observed_orcids":["https://orcid.org/0000-0003-0512-5876"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Val\u00e9rie Le Masson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074900911","display_name":"Yolande Lemeille","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124863","display_name":"Centre Hospitalier Sainte-Anne","ror":"https://ror.org/02kxjxy06","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124863"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Yolande Lemeille","raw_affiliation_strings":["Department of Laboratory Medicine, Section of Psychopharmacology, \u2020Department of Pharmacy, and \u2021Department of Medical Information, Section of Epidemiology, Centre Hospitalier Sainte-Anne, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Laboratory Medicine, Section of Psychopharmacology, \u2020Department of Pharmacy, and \u2021Department of Medical Information, Section of Epidemiology, Centre Hospitalier Sainte-Anne, Paris, France","institution_ids":["https://openalex.org/I4210124863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010349909","display_name":"Sophie Brovedani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124863","display_name":"Centre Hospitalier Sainte-Anne","ror":"https://ror.org/02kxjxy06","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124863"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Sophie Brovedani","raw_affiliation_strings":["Department of Laboratory Medicine, Section of Psychopharmacology, \u2020Department of Pharmacy, and \u2021Department of Medical Information, Section of Epidemiology, Centre Hospitalier Sainte-Anne, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Laboratory Medicine, Section of Psychopharmacology, \u2020Department of Pharmacy, and \u2021Department of Medical Information, Section of Epidemiology, Centre Hospitalier Sainte-Anne, Paris, France","institution_ids":["https://openalex.org/I4210124863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054346738","display_name":"Pascal Paubel","orcid":"https://orcid.org/0000-0002-9301-7826","observed_orcids":["https://orcid.org/0000-0002-9301-7826","https://orcid.org/0009-0009-8851-3372"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pascal Paubel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5008932546","display_name":"Marie\u2010Liesse Piketty","orcid":"https://orcid.org/0000-0002-9410-4796","observed_orcids":["https://orcid.org/0000-0002-9410-4796"]},"institutions":[{"id":"https://openalex.org/I4210124863","display_name":"Centre Hospitalier Sainte-Anne","ror":"https://ror.org/02kxjxy06","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124863"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Marie-Liesse Piketty","raw_affiliation_strings":["Department of Laboratory Medicine, Section of Psychopharmacology, \u2020Department of Pharmacy, and \u2021Department of Medical Information, Section of Epidemiology, Centre Hospitalier Sainte-Anne, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Laboratory Medicine, Section of Psychopharmacology, \u2020Department of Pharmacy, and \u2021Department of Medical Information, Section of Epidemiology, Centre Hospitalier Sainte-Anne, Paris, France","institution_ids":["https://openalex.org/I4210124863"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5008932546","https://openalex.org/A5010349909","https://openalex.org/A5074900911","https://openalex.org/A5111728405"],"corresponding_institution_ids":["https://openalex.org/I4210124863"],"apc_list":null,"apc_paid":null,"fwci":0.4198,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.57820407,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"32","issue":"6","first_page":"757","last_page":"761"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9506999850273132,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9506999850273132,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.043699998408555984,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cyamemazine","display_name":"cyamemazine","score":1.0},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":1.0},{"id":"https://openalex.org/keywords/paliperidone","display_name":"paliperidone","score":1.0},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.847000002861023},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.42800000309944153},{"id":"https://openalex.org/keywords/antipsychotic-polypharmacy","display_name":"antipsychotic polypharmacy","score":0.7599999904632568},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.734000027179718},{"id":"https://openalex.org/keywords/phenothiazines","display_name":"phenothiazines","score":0.753000020980835}],"concepts":[{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.9425173997879028},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5303443670272827},{"id":"https://openalex.org/C2780272996","wikidata":"https://www.wikidata.org/wiki/Q1261151","display_name":"Therapeutic drug monitoring","level":3,"score":0.4280538558959961},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40170109272003174},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.3735331892967224},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3558151125907898},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.2687646448612213},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0969482958316803}],"mesh":[{"descriptor_ui":"D000068882","descriptor_name":"Paliperidone Palmitate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007555","descriptor_name":"Isoxazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010640","descriptor_name":"Phenothiazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010640","descriptor_name":"Phenothiazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013056","descriptor_name":"Spectrophotometry, Ultraviolet","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/ftd.0b013e3181fa57fe","doi":"https://doi.org/10.1097/ftd.0b013e3181fa57fe","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ftd.0b013e3181fa57fe","pdf_url":null,"source":{"id":"https://openalex.org/S179268941","display_name":"Therapeutic Drug Monitoring","issn_l":"0163-4356","issn":["0163-4356","1536-3694"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Drug Monitoring","raw_type":"journal-article"},{"id":"pmid:21068648","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21068648","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic drug monitoring","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320338413","display_name":"Cilag","ror":"https://ror.org/02fe4h741"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W1708423019","https://openalex.org/W1910227173","https://openalex.org/W1965930339","https://openalex.org/W1979193458","https://openalex.org/W1981367166","https://openalex.org/W1988912205","https://openalex.org/W1990103265","https://openalex.org/W1996288108","https://openalex.org/W2000106454","https://openalex.org/W2001119598","https://openalex.org/W2003056444","https://openalex.org/W2006409616","https://openalex.org/W2012554561","https://openalex.org/W2018434135","https://openalex.org/W2018518279","https://openalex.org/W2034400329","https://openalex.org/W2041253701","https://openalex.org/W2043985392","https://openalex.org/W2046744474","https://openalex.org/W2049754460","https://openalex.org/W2055609884","https://openalex.org/W2062106705","https://openalex.org/W2064104740","https://openalex.org/W2065409386","https://openalex.org/W2085696296","https://openalex.org/W2125522375","https://openalex.org/W2127423678","https://openalex.org/W2156883225","https://openalex.org/W2267542151","https://openalex.org/W2312219744","https://openalex.org/W2316397588","https://openalex.org/W2319310294","https://openalex.org/W2319976610"],"related_works":["https://openalex.org/W2085696296","https://openalex.org/W2585125306","https://openalex.org/W2058201916","https://openalex.org/W2003056444","https://openalex.org/W2606999690","https://openalex.org/W2417149763","https://openalex.org/W2053664234","https://openalex.org/W1970839880","https://openalex.org/W6977598641","https://openalex.org/W2061990639"],"abstract_inverted_index":{"Administration":[0],"of":[1,26,33,46,87,129,163,170],"cyamemazine,":[2],"an":[3,150,168],"antipsychotic":[4,12],"drug":[5],"with":[6,10,18,41,64,79,146],"anxiolytic":[7],"properties,":[8],"together":[9],"other":[11,177],"agents":[13],"is":[14,166],"common":[15],"in":[16,37,92,99,113,122,149],"patients":[17,39,61],"schizophrenia.":[19],"This":[20],"retrospective":[21],"study":[22],"investigated":[23],"the":[24,29,93,100,106,114,123,127,161],"effects":[25],"cyamemazine":[27,55,94,115,142,147,159],"on":[28],"steady-state":[30],"plasma":[31,85,135],"concentrations":[32,70],"risperidone":[34,65,88,130,164],"and":[35,59,165],"9-hydroxyrisperidone":[36,107,132],"47":[38,50],"treated":[40,63],"1":[42],"to":[43],"12":[44],"mg/day":[45],"risperidone.":[47],"Of":[48],"these":[49],"patients,":[51],"24":[52],"were":[53,62,71],"receiving":[54],"comedication":[56],"(\"cyamemazine\"":[57],"group)":[58],"23":[60],"alone":[66],"(\"control\"":[67],"group).":[68,125],"Plasma":[69],"measured":[72],"using":[73],"a":[74],"high-performance":[75],"liquid":[76],"chromatographic":[77],"method":[78],"photodiode-array":[80],"ultraviolet":[81],"detection.":[82],"The":[83],"median":[84,108],"concentration":[86,109,136],"was":[89,110,137],"significantly":[90,111,139],"higher":[91],"group":[95,102,116],"(31.5":[96],"ng/mL)":[97],"than":[98],"control":[101,124],"(5.0":[103],"ng/mL),":[104],"whereas":[105],"lower":[112],"(16.5":[117],"ng/mL":[118,121],"versus":[119],"39.0":[120],"However,":[126],"sum":[128],"plus":[131],"(active":[133],"moiety)":[134],"not":[138],"affected":[140],"by":[141],"comedication.":[143],"A":[144],"combination":[145],"resulted":[148],"inverted":[151],"metabolic":[152],"ratio":[153],"(risperidone/9-hydroxyrisperidone).":[154],"These":[155],"findings":[156],"suggest":[157],"that":[158],"inhibits":[160],"9-hydroxylation":[162],"probably":[167],"inhibitor":[169],"cytochrome":[171],"P450":[172],"2D6":[173],"as":[174],"are":[175],"many":[176],"phenothiazine":[178],"drugs.":[179]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}